CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- $93.15M
- P/E (TTM)
- –
- Dividend yield
- –
Cellectis S.A. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q4 25 | Q2 25 | Q4 24 | Q2 24 | Q4 23 | Q2 23 | Q4 22 | Q2 22 | Q4 21 | Q2 21 | Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plants [member] | – | – | – | – | – | – | – | – | $42.00K | – | $11.73M | – | – | – |
| Therapeutics [member] | – | – | – | – | – | – | – | – | $1.31M | – | -$552.00K | – | – | – |
By region
| Revenue | Q2 26 | Q4 25 | Q2 25 | Q4 24 | Q2 24 | Q4 23 | Q2 23 | Q4 22 | Q2 22 | Q4 21 | Q2 21 | Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | $5.23M | – | $16.73M | – | $8.06M | – | $178.00K | – | $1.31M | – | -$552.00K | – | 100.0% | -68.7% |
| United States | – | – | – | – | $0 | – | $0 | – | $0 | – | $11.73M | – | – | – |
From the segment and revenue-disaggregation notes of Cellectis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.